In summary, the ONWARDS trials demonstrated the potential of icodec as an effective treatment option for T2D, with similar, superior or non-inferior efficacy to once-daily basal insulin analogues and a comparable safety profile, independently of age, ethnicity, renal function, and previously use of GLP-1 analogues [55]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.